From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade namesEbernet
Legal status
Legal status
  • US: Not FDA approved
CAS Number
PubChem CID
Chemical and physical data
Molar mass329.22 g·mol−1
3D model (JSmol)

Eberconazole is an antifungal drug. As a 1% topical cream, it is an effective treatment for dermatophytosis, candidiasis, and pityriasis.[1][2][3]

It was approved for use in Spain in 2015 and is sold under the trade name Ebernet.[4] It is also approved for use in Panama, Guatemala, Costa Rica, Honduras, and the Dominican Republic.[1]


  1. ^ a b "Ebernet". NewBridge Pharmaceuticals.
  2. ^ Del Palacio, A; Ortiz, F. J.; Pérez, A; Pazos, C; Garau, M; Font, E (2001). "A double-blind randomized comparative trial: Eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections". Mycoses. 44 (5): 173–80. doi:10.1046/j.1439-0507.2001.00632.x. PMID 11486455.
  3. ^ Repiso Montero, T; López, S; Rodríguez, C; Del Rio, R; Badell, A; Gratacós, M. R. (2006). "Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: Multicenter, randomized, double-blind, comparative trial with miconazole 2% cream". International Journal of Dermatology. 45 (5): 600–4. doi:10.1111/j.1365-4632.2006.02841.x. PMID 16700802.
  4. ^ "Eberconazole". Drugs.com.